Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Heart Failure Drugs: β-Blockers

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Prompt-directed ambient artificial intelligence for automated multidisciplinary tumor board documentation.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Same author

FGF Receptor Signaling in Oligodendrocytes Regulates Synaptic Plasticity, Learning, and Memory in the Adult Brain.

Glia·2025

Same author

Selection of human embryo for IVF treatment using ensemble machine learning technique.

Morphologie : bulletin de l'Association des anatomistes·2025

Same author

Exploring the diagnostic and prognostic utility of resting state functional MRI connectivity in acute/sub-acute TBI.

medRxiv : the preprint server for health sciences·2025

Same author

Magnetic resonance (MR) and computed tomography (CT) imaging of temporal lobe encephalocele-associated epilepsy: a pictorial review.

Clinical radiology·2025

Same author

Venous malformations as a rare cause of lower gastrointestinal bleeding in a young patient with Blue Rubber Bleb Nevus Syndrome.

Acta gastro-enterologica Belgica·2025

Search research articles

Related Experiment Video

Updated: Nov 4, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia.

R Bansal¹, A Mahajan¹, S Vichare¹

¹Holy Family Hospital, Mumbai, Maharashtra, India.

Journal of Postgraduate Medicine

|May 28, 2021

Summary

Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare, fatal heart condition. Cardiac sympathetic denervation (CSD) effectively managed a patient with CPVT when other treatments failed, preventing syncope and arrhythmias.

Keywords:

Cardiac sympathectomy sudden death syncope

More Related Videos

Location, Dissection, and Analysis of the Murine Stellate Ganglion

Location, Dissection, and Analysis of the Murine Stellate Ganglion

Published on: December 22, 2020

Ablation of Ischemic Ventricular Tachycardia Using a Multipolar Catheter and 3-dimensional Mapping System for High-density Electro-anatomical Reconstruction

Ablation of Ischemic Ventricular Tachycardia Using a Multipolar Catheter and 3-dimensional Mapping System for High-density Electro-anatomical Reconstruction

Published on: January 31, 2019

Related Experiment Videos

Last Updated: Nov 4, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Location, Dissection, and Analysis of the Murine Stellate Ganglion

Location, Dissection, and Analysis of the Murine Stellate Ganglion

Published on: December 22, 2020

Ablation of Ischemic Ventricular Tachycardia Using a Multipolar Catheter and 3-dimensional Mapping System for High-density Electro-anatomical Reconstruction

Ablation of Ischemic Ventricular Tachycardia Using a Multipolar Catheter and 3-dimensional Mapping System for High-density Electro-anatomical Reconstruction

Published on: January 31, 2019

Area of Science:

Cardiology
Genetics
Electrophysiology

Background:

Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare, life-threatening inherited arrhythmogenic disorder.
Diagnosis and management of CPVT present significant clinical challenges.
Recurrent exertional syncope and ventricular ectopy are key clinical indicators.

Observation:

A 21-year-old male presented with recurrent exertional syncope and multifocal ventricular ectopy.
CPVT diagnosis was established clinically, despite the absence of some classic findings.
Standard treatments including lifestyle changes and medications were ineffective.

Findings:

The patient underwent cardiac sympathetic denervation (CSD) as a therapeutic intervention.
CSD demonstrated significant effectiveness in managing the patient's condition.
No exertional symptoms or syncope recurrence were observed during a 1-year follow-up.

Implications:

This case supports the efficacy of CSD as a treatment option for refractory CPVT.
Cardiac sympathetic denervation offers a viable therapeutic strategy for managing this challenging arrhythmia.
Further evidence strengthens the role of CSD in the clinical management of CPVT.